Wednesday, October 4, 2017

Crystal Bioscience Acquired By Ligand For Up To $30.5M

Emeryville-based Crystal Bioscience, the developer of chicken-derived, human antibody production technology, has been acquired by Ligand Pharmaceuticals. Ligand said it agreed to pay $25M in cash plus additional potential payments of up to $10.5M based on success-based milestones and revenue sharing for Crystal Bioscience.